SEC inhibitor KL-1 (Synonyms: KL-1) |
| Catalog No.GC38063 |
El inhibidor de SEC KL-1 (KL-1), un compuesto principal peptidomimético, es un inhibidor potente y selectivo del complejo de superelongaciÓn (SEC) e interrumpe la interacciÓn entre la proteÍna de andamiaje de SEC AFF4 y P-TEFb, lo que da como resultado una liberaciÓn deficiente de Pol II. de los sitios de pausa proximales al promotor y una tasa promedio reducida de elongaciÓn de la transcripciÓn procesiva. El inhibidor de SEC KL-1 exhibe un efecto inhibitorio dependiente de la dosis sobre la interacciÓn AFF4-CCNT1 con un Ki de 3,48 μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 900308-84-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SEC inhibitor KL-1 (KL-1), a peptidomimetic lead compound, is a potent, selective super elongation complex (SEC) inhibitor and disrupts the interaction between the SEC scaffolding protein AFF4 and P-TEFb, resulting in impaired release of Pol II from promoter-proximal pause sites and a reduced average rate of processive transcription elongation. SEC inhibitor KL-1 exhibits an dose-dependent inhibitory effect on AFF4-CCNT1 interaction with a Ki of 3.48 μM[1].
[1]. Liang K, et al. Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced CancerTherapy. Cell. 2018 Oct 18;175(3):766-779.
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *